KLSE (MYR): PHARMA (7081)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.375
Today's Change
-0.025 (6.25%)
Day's Change
0.37 - 0.40
Trading Volume
5,332,500
2024-11-29
2024-11-27
2024-11-27
2024-11-27
2024-11-26
Powerplay666
1,023 posts
Posted by Powerplay666 > 2021-06-07 19:43 | Report Abuse
Interesting clue to note that receivables as of Q1 stood at 544 million. We also know that the vaccine business took off from March onwards so the added revenue generated in Q2 will be quite significant on top of the outstanding receivables. Receivables are basically incoming revenue that will be recognised in Q2 once delivered and invoiced to the customer. Based on the above information, its reasonable to expect revenue for Q2 to exceed well over 1billion (it was 793 million in Q1). Earnings should hit around 35 plus million or thereabouts (compared to 23 million in Q1). So on top of the huge receivables of 544 million which will translate into revenue in Q2, we expect pharma to do another 600 million plus in business to hit the 1b revenue mark. Earnings of 35 million will translate into around 13 sen eps, compared to the Q1 eps of 8 sen. This is a conservative estimate because I am just basing on vaccine additional business and not assuming the non vaccine business growth.
Biggest clue to knowing if a company's revenue will grow qoq is to compare the company's receivables qoq to see if its growing or decreasing. In Pharma case, receivables have shot up (320mill in q4 vs 544 million in Q1).
We can look forward to an excellent Q2 and even better q3. Not to mention the bonus issue 4 for 1 which will goreng the share price in the run up to ex date.
My sifu has predicted pre adjusted price of rm11 to 12 by ex date.
At current prices, its considered a bargain after the heavy retracement. Let's not forget only 4% of Malaysians have been vaccinated thus far!